Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

Replicel Life Sciences Inc > RepliCel Life Sciences Announces Reinstatement of Trading &
View:
Post by lscfa on Oct 17, 2024 3:32pm

RepliCel Life Sciences Announces Reinstatement of Trading &

RepliCel Life Sciences Announces Reinstatement of Trading & Conditional Acceptance for Proposed Transaction
 
VANCOUVER, BC, CANADA – October 17, 2024 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), announces that, following a reinstatement review by the TSX Venture Exchange (the “Exchange”), the Company’s common shares are expected to be reinstated for trading.
 
As of June 30, 2024, the Company’s working capital deficiency was approximately $(2,071,403). At this time, the Company intends to manage its working capital concerns through its secured loan (the “Loan”) with Andrew Schutte, the President and Chief Executive Officer of the Company. For additional details relating to the Loan, see the Company’s news release dated April 17, 2024 filed under the Company’s profile on www.sedarplus.ca.
 
In addition, the Company is pleased to announce that it has received conditional acceptance from the Exchange for its proposed disposition of assets to 1456390 B.C. Ltd., a nonarm’s length private British Columbia company controlled by Andrew Schutte. The transaction will be subject to approval by the Company’s shareholders, which the Company will seek at a meeting of its shareholders (the “Meeting”). The Company anticipates that it will hold the Meeting before December 31, 2024. For additional details relating to the proposed transaction, see the Company’s news release dated August 28, 2024 filed under the Company’s profile on www.sedarplus.ca. Additional updates relating to the proposed transaction will be provided in future news releases.
 
  
Comment by Ingiboy on Oct 18, 2024 12:02am
When will the trading halt be lifted ?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities